Xlife Sciences AG Reports Portfolio Growth and Strategic Advances

Zurich - Xlife Sciences AG announced findings from their 2023 Valuation Report, detailing significant growth in their portfolio. As of December 31, 2023, the portfolio was valued between CHF 611.7 million and CHF 747.8 million, seeing an increase from the previous year's values.

The report, carried out by CYLAD Experts, evaluated 18 out of the 25 project companies within Xlife Sciences' portfolio. Significant value contributors include six project companies such as alytas therapeutics GmbH and Veraxa Biotech AG, which collectively account for 84% of the portfolio's value.

CEO Oliver R. Baumann commented on the value increase, highlighting the potential leverage for shareholders and affirming the focus on early-stage projects. The report indicates that 70% of the portfolio is in the "Proof of Concept" phase, with another 20% reaching clinical development.